2024, Peripheral Arterial Disease and Stents

Intravascular Ultrasound Outperforms Angiography for Peripheral Artery Disease Treatment

DAIC

APRIL 11, 2024

The study, called IVUS-DCB, is the first randomized controlled trial to demonstrate the clinical benefits of using IVUS in angioplasty procedures for peripheral artery disease (PAD), a condition in which plaque builds up in arteries in the legs. The study was funded by Medtronic, Inc. and Korea United Pharm.

Peripheral Arterial Disease

Peripheral Arterial Disease Ultrasound Angioplasty Plaque

Medtronic Releases Atherectomy Studies at VIVA 2024

DAIC

NOVEMBER 8, 2024

tim.hodson Fri, 11/08/2024 - 10:10 Medtronic recently announced results from two studies evaluating the utility of atherectomy for peripheral endovascular interventions. Results from both analyses were released at the Vascular InterVentional Advances (VIVA) 2024 conference in Las Vegas. DA+DCB versus 5.9%

Stents

Stents Stent Angioplasty Peripheral Arterial Disease

R3 Vascular Appoints Josh Smale as Vice President of Global Clinical and Scientific Affairs

DAIC

JULY 11, 2024

a Mountain View, CA-based developer of novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), has announced the appointment of Josh Smale as its Vice President of Global Clinical and Scientific Affairs. Medical device company R3 Vascular Inc., Image courtesy: R3 Vascular Inc.

Peripheral Arterial Disease

Peripheral Arterial Disease Stents Stent Education

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

AI Measures Fat Around the Heart, a Key to Predicting Heart Attacks

DAIC

FEBRUARY 14, 2024

Encouraged by the early clinical results, Efemoral Medical is now developing an additional device for treating below-the-knee (infrapopliteal) arteries in patients with CLTI. Diseased human arteries are most simply, reliably, and successfully treated with drug-eluting, balloon-expandable stents," said Lewis B.

Heart Attack

Heart Attack Heart attacks Peripheral Arterial Disease Ischemia

Elixir Medical Granted FDA Breakthrough Device Designation for DynamX Bioadaptor

DAIC

JUNE 18, 2024

The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease. 1 To date, interventional treatment of coronary artery disease with drug-eluting stents has been able to establish flow angiographically. of the U.S.

Coronary Artery Disease

Coronary Artery Disease Technology Stents Stent

Clinical Outcomes of Non-Stent Based Interventions for Symptomatic Below-the-Knee Peripheral Artery Disease in the Excellence in Peripheral Artery Disease (XLPAD) Registry

The American Journal of Cardiology

AUGUST 5, 2024

Publication date: Available online 5 August 2024 Source: The American Journal of Cardiology Author(s): Sameh Sayfo, Zachary P. Rosol, David Fernandez Vazquez, Mufaddal Mamawala, Blake M. Bruneman, Sarah G. Weideman, Kennedy S. Adelman, Minseob Jeong, Bala Ramanan, Shirling Tsai, Nicolas W. Shammas, Peter P. Chu, Bertram L.

Peripheral Arterial Disease

Peripheral Arterial Disease Stent Stents Outcomes

Elixir Medical PINNACLE I Study of LithiX IVL System Meets Primary Endpoints of Clinical Success

DAIC

MAY 30, 2024

Clinical success was defined as optimal stent expansion after final treatment with no in-hospital major adverse cardiovascular event (MACE). stent expansion at Maximum Calcium Site 96.7% stent expansion at Maximum Calcium Site 96.7% Shown here: Elixir Medical CEO Motasim Sirhan.

Stents

Stents Stent Peripheral Arterial Disease Cardiovascular Disease

FDA Breakthrough Device Designation for Biotronik Freesolve Below-the-Knee Resorbable Magnesium Scaffold (RMS)

DAIC

MARCH 20, 2024

milla1cf Wed, 03/20/2024 - 18:50 March 20, 2024 — Biotronik has been granted Breakthrough Device Designation (BDD) from the US Food and Drug Administration (FDA) for the Freesolve below-the-knee resorbable magnesium scaffold (BTK RMS). degradation of magnesium observed 12 months after implantation in coronary arteries.4

Peripheral Arterial Disease

Peripheral Arterial Disease Innovation Technology Coronary Artery Disease

SCAI, SIR, and SVS Jointly Publish Proceedings from Multispecialty Peripheral IVUS Roundtable

DAIC

JANUARY 9, 2024

The roundtable provided a unique opportunity to identify knowledge gaps and discuss how IVUS can enhance our understanding and treatment of peripheral arterial and deep venous pathology." They also emphasized the need for further research and evidence to support the integration of IVUS into routine clinical practice.

Peripheral Arterial Disease

Peripheral Arterial Disease Ultrasound Angioplasty Interventional Cardiology

Clinical utility of lipoprotein(a): an interventionist’s perspective

The British Journal of Cardiology

AUGUST 1, 2024

Large-scale observational data have demonstrated a robust, independent association of elevated lipoprotein(a) (Lp[a]) levels with atherosclerotic cardiovascular disease (CVD), stroke, and peripheral artery disease.

Peripheral Arterial Disease

Peripheral Arterial Disease Myocardial Infarction Plaque Cardiovascular Disease

Abstract 4139108: Identifying Predictors of Durable Treatment Response among Patients with Claudication; A Secondary Analysis of the CLEVER Trial

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4139108-A4139108, November 12, 2024. Background:Symptomatic peripheral artery disease (PAD) is prevalent and targeted therapies include optimal medical care (OMC), supervised exercise therapy (SET) and revascularization (ST).

Peripheral Arterial Disease

Peripheral Arterial Disease Quality of Life Exercise Stents

HonorHealth Research Institute First in Southwest to Implant New Stroke Prevention Stent

DAIC

JUNE 4, 2024

a vascular surgeon and director of HonorHealth’s vascular services, said the device avoids carotid endarterectomy, a previous method for removing plaque from carotid arteries, which involves a surgical procedure requiring an incision directly into the neck. who has suffered from peripheral artery disease for years.

Stent

Stent Stents Research Stroke

One-Year BIONETIC-I Study Results Show Safety and Effectiveness of Iliac Artery Treatment With BIOTRONIK’s Dynetic-35 Cobalt Chromium Balloon-Expandable Stent System

DAIC

MAY 30, 2024

milla1cf Thu, 05/30/2024 - 10:14 May 30, 2024 — B iotronik announced the presentation of the 12-month results from the BIONETIC-I study this week at LINC 2024. BIOTRONIK Dynetic-35 cobalt chromium balloon-expandable stent for peripheral iliac lesions: 12-month results of the BIONETIC-I Multi-Center study.

Stent

Stent Stents Peripheral Arterial Disease Innovation

Johnson and Johnson to Acquire Shockwave Medical

DAIC

APRIL 5, 2024

Getty Images milla1cf Fri, 04/05/2024 - 09:57 April 5, 2024 — Johnson & Johnson and Shockwave Medical , Inc. IVL is a minimally invasive, catheter-based treatment for calcified arterial lesions, which can reduce blood flow and cause pain or heart attack. in 2024 and approximately $0.17 billion including cash acquired.

Cardiovascular Interventions

Cardiovascular Interventions Technology Innovation Angina

Cardiovascular Update

Intravascular Ultrasound Outperforms Angiography for Peripheral Artery Disease Treatment

Medtronic Releases Atherectomy Studies at VIVA 2024

R3 Vascular Appoints Josh Smale as Vice President of Global Clinical and Scientific Affairs

Webinars

AI Measures Fat Around the Heart, a Key to Predicting Heart Attacks

Elixir Medical Granted FDA Breakthrough Device Designation for DynamX Bioadaptor

Clinical Outcomes of Non-Stent Based Interventions for Symptomatic Below-the-Knee Peripheral Artery Disease in the Excellence in Peripheral Artery Disease (XLPAD) Registry

Elixir Medical PINNACLE I Study of LithiX IVL System Meets Primary Endpoints of Clinical Success

FDA Breakthrough Device Designation for Biotronik Freesolve Below-the-Knee Resorbable Magnesium Scaffold (RMS)

SCAI, SIR, and SVS Jointly Publish Proceedings from Multispecialty Peripheral IVUS Roundtable

Clinical utility of lipoprotein(a): an interventionist’s perspective

Abstract 4139108: Identifying Predictors of Durable Treatment Response among Patients with Claudication; A Secondary Analysis of the CLEVER Trial

HonorHealth Research Institute First in Southwest to Implant New Stroke Prevention Stent

One-Year BIONETIC-I Study Results Show Safety and Effectiveness of Iliac Artery Treatment With BIOTRONIK’s Dynetic-35 Cobalt Chromium Balloon-Expandable Stent System

Johnson and Johnson to Acquire Shockwave Medical

Stay Connected